31.10.2024 11:54:28
|
Merck Cuts FY24 Earnings View, Narrows Sales Forecast After Weak Q3 Earnings - Update
(RTTNews) - Drug major Merck & Co., Inc. (MRK), while reporting weak third-quarter earnings, on Thursday trimmed its fiscal 2024 adjusted earnings view, and narrowed sales forecast.
In pre-market activity on the NYSE, Merck shares were down around 0.3 percent to trade at $104.50.
Looking ahead for fiscal 2024, the company now expects adjusted earnings per share to be between $7.72 and $7.77, lower than previous estimate of $7.94 and $8.04. The outlook reflects negative impact of $0.24 per share related to business development transactions with Curon Biopharmaceutical and Daiichi Sankyo.
Further, the company updated expected worldwide sales range to be between $63.60 billion and $64.10 billion, compared to previous estimate of $63.40 billion and $64.40 billion.
Analysts on average expect the company to report earnings of $7.74 per share on sales of $64.15 billion, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
In its third quarter, Merck's earnings decreased from last year. The company's bottom line totaled $3.157 billion or $1.24 per share, down 33 percent from $4.745 billion or $1.86 per share last year.
Adjusted earnings were $3.985 billion or $1.57 per share for the period, compared to $5.427 billion or $2.13 per share a year ago.
The company's sales for the quarter rose 4.4 percent to $16.657 billion from $15.962 billion last year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
17.01.25 |
Gewinne in New York: Dow Jones bewegt sich nachmittags im Plus (finanzen.at) | |
17.01.25 |
Börse New York in Grün: S&P 500 nachmittags stärker (finanzen.at) | |
17.01.25 |
Dow Jones aktuell: Dow Jones notiert am Mittag im Plus (finanzen.at) | |
17.01.25 |
Starker Wochentag in New York: S&P 500 klettert mittags (finanzen.at) | |
17.01.25 |
NYSE-Handel: Dow Jones zum Start fester (finanzen.at) | |
14.01.25 |
Starker Wochentag in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone (finanzen.at) | |
14.01.25 |
Zuversicht in New York: So performt der Dow Jones nachmittags (finanzen.at) | |
14.01.25 |
Börse New York in Rot: Dow Jones zeigt sich am Dienstagmittag schwächer (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 95,80 | -1,74% |